Biotech Values

[masterlongevity]

I bought $blue yesterday as well. When i see a fundamental flaw in media and bankers logic " its bad news they wont give us frequent updates of data for our own selfish interest instead of letting it mature in the interests of the data integrity and patients" then i always try to buy. Too many analysts and media dont understand limitations and ramifications of frequent data looks in an ongoing trial